Zim Laboratories reported a solid Q3 FY26, with total operating income up 12.8% YoY to ₹108.7 Cr.

EBITDA also grew 9.1% YoY to ₹14.5 Cr, and the company achieved a positive PAT of ₹4.4 Cr, recovering from a previous quarter's loss.

For the 9M FY26, revenue remained largely flat at ₹269.1 Cr, while EBITDA was ₹28 Cr.

Growth in Q3 was led by the Pharma segment, contributing ₹78.6 Cr (+6.4% YoY), and a significant 34% YoY jump in the Nutra business to ₹30 Cr.

Exports were a key driver, making up 88% of Q3 revenue at ₹96.1 Cr (+23% YoY). Strategically, the Board approved raising ₹35 Cr through a preferential share issue to Florintree Trinex LLP.

These funds will fuel a dedicated facility for Star Product 2 targeting developed markets, a new nutraceutical plant, and CAPA remediation efforts.

The company has implemented most of its CAPA remediation plan and expects to be ready for inspections from March 2026. R&D remains a priority, with ₹7.5 Cr spent in Q3, building a robust pipeline of innovative products that contributed 12.2% to Q3 operating income.

The leadership team has also been strengthened with key hires to boost organizational capabilities and drive future growth.